Angela M DeMichele, MD MSCE

faculty photo
Alan and Jill Miller Professor in Breast Cancer Excellence
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-153
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology

Description of Clinical Expertise

breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorship

Selected Publications

Brown JC, Sarwer DB, Troxel AB, Sturgeon K, DeMichele AM, Denlinger CS, Schmitz KH. : A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity. Breast Cancer Research & Treatment 189: 145-154, August 2021.

Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park YH, Brufsky A, Theall KP, Huang X, McRoy L, Bananis E, Turner NC: Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. The Oncologist 26: 1339-1346, August 2021.

Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD: Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131 Journal of Clinical Oncology 39(23): 2539-2551, August 2021.

Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA, Mamtani R, Huang AC. : CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine 27: 1280-1289, July 2021.

J J Harding, M Telli, P Munster, M. H Voss , J. R Infante , A DeMichele, M Dunphy , M. H Le, C Molineaux , K Orford, F Parlati, S. H Whiting , M. K Bennett, N.M Tannir, F Meric-Bernstam : A Phase 1 Dose-Escalation and Expansion Study of Telaglenastat in Patients With Advanced or Metastatic Solid Tumors. Clinical Cancer Research July 2021.

Davey S, Grover S, Bilker WB, Setlhako DI, Ralefala TB, Manshimba P, Gross R, DeMichele A, Shulman LN, Martei YM. : Retrospective cohort analysis of prescription patterns of cancer medications during periods of drug stockouts in Botswana. British Medical Journal 11(7), July 2021.

Brown JC, Sarwer DB, Troxel AB, Sturgeon K, DeMichele AM, Denlinger CS, Schmitz KH: A randomized trial of exercise and diet on health-related quality of life in survivors of breast cancer with overweight or obesity. Cancer June 2021.

Paoletti C, Regan MM, Niman SM, Dolce EM, Darga EP, Liu MC, Marcom PK, Hart LL, Smith JW 2nd, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Brown ME, McCormack RT, Hayes DF.: Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. NPJ Breast Cancer 7, June 2021.

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ.: Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell 39(7), June 2021.

Rocque GB, Williams CP, Andrews C, Childers TC, Wiseman KD, Gallagher K, Tung N, Balch A, Lawhon VM, Ingram SA, Brown T, Kaufmann T, Smith ML, DeMichele A, Wolff AC, Wagner L.: Patient perspectives on chemotherapy de-escalation in breast cancer. Cancer Medicine May 2021.

back to top
Last updated: 08/18/2021
The Trustees of the University of Pennsylvania